Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Appointed CFO Quarterly results Acq. announced Director departure CC transcript
|
ACHIEVE LIFE SCIENCES, INC. (ACHV)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/14/2023 |
8-K
| Quarterly results
Docs:
|
"Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE, Wash and VANCOUVER, British Columbia, August 14, 2023 — Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Highlights • Publication of Phase 3 ORCA-2 trial results in the Journal of the American Medical Association • Reported statistically significant smoking cessation benefit for cytisinicline in the confirmatory Phase 3 ORCA-..." |
|
05/09/2023 |
8-K
| Quarterly results
Docs:
|
"Consolidated Statements of Loss Three months ended March 31, 2023 2022 Operating expenses: Research and development 5,534 4,388 General and administrative 3,044 2,838 Total operating expenses 8,578 7,226 Loss from operations Other income Net loss $ $ Basic and diluted net loss per share $ $ Weighted average number of basic and diluted common shares 17,917,769 9,458,745 Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets: Cash and cash equivalents $ 16,514 $ 24,771 Prepaid expenses and other current assets 1,710 2,559 Other assets and restricted cash 68 123 Right-of-use assets 109 66 License agreement 1,363 1,418 Goodwill 1,034 1,034 Total assets $ 20,798 $ 29,971 Liabilities and stockholders' equity: Accounts payable and accrued liabilities $ 3,872 $ 5,470 Current portion..." |
|
03/16/2023 |
8-K
| Quarterly results |
11/14/2022 |
8-K
| Quarterly results |
08/11/2022 |
8-K
| Quarterly results |
05/12/2022 |
8-K
| Quarterly results |
03/10/2022 |
8-K
| Quarterly results |
11/09/2021 |
8-K
| Quarterly results |
05/13/2021 |
8-K
| Quarterly results |
03/11/2021 |
8-K
| Quarterly results |
11/12/2020 |
8-K
| Quarterly results |
08/06/2020 |
8-K
| Quarterly results |
05/14/2020 |
8-K
| Quarterly results |
03/13/2020 |
8-K
| Quarterly results |
11/06/2019 |
8-K
| Quarterly results |
08/08/2019 |
8-K
| Quarterly results |
05/15/2019 |
8-K
| Quarterly results |
03/14/2019 |
8-K
| Quarterly results |
08/08/2018 |
8-K
| Quarterly results |
11/09/2017 |
8-K
| Quarterly results |
05/15/2017 |
8-K
| Form 8-K - Current report |
02/23/2017 |
8-K
| Form 8-K - Current report |
11/10/2016 |
8-K
| Quarterly results |
08/04/2016 |
8-K
| Quarterly results |
05/12/2016 |
8-K
| Form 8-K - Current report |
03/09/2016 |
8-K
| Quarterly results |
11/12/2015 |
8-K
| Quarterly results |
08/13/2015 |
8-K
| Quarterly results |
05/14/2015 |
8-K
| Quarterly results |
03/26/2015 |
8-K
| Quarterly results |
10/30/2014 |
8-K
| Quarterly results |
08/07/2014 |
8-K
| Quarterly results
Docs:
|
"Employment Agreement between OncoGenex Pharmaceuticals, Inc. and John Bencich",
"OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, August 7, 2014 - OncoGenex Pharmaceuticals, Inc. today provided a summary of clinical developments and announced second quarter 2014 financial results. Clinical Developments and Anticipated Milestones",
"OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer BOTHELL, WA, and VANCOUVER, British Columbia, August 7, 2014" |
|
04/30/2014 |
8-K
| Quarterly results |
03/11/2014 |
8-K
| Quarterly results |
|
|
|